Zogenix, Inc. Logo

Zogenix, Inc.

0M3O.L

(0.0)
Stock Price

40,75 USD

-61.2% ROA

10.55% ROE

-6.3x PER

Market Cap.

0,00 USD

94.14% DER

0% Yield

4.99% NPM

Zogenix, Inc. Stock Analysis

Zogenix, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Zogenix, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Zogenix, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Zogenix, Inc. Technical Stock Analysis
# Analysis Recommendation

Zogenix, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Zogenix, Inc. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 23.442.000 100%
2011 37.576.000 37.61%
2012 44.326.000 15.23%
2013 33.012.000 -34.27%
2014 40.531.000 18.55%
2015 27.182.000 -49.11%
2016 28.850.000 5.78%
2017 9.821.000 -193.76%
2018 0 0%
2019 3.648.000 100%
2020 13.643.000 73.26%
2021 106.432.000 87.18%
2022 15.801.000.000 99.33%
2023 14.488.000.000 -9.06%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Zogenix, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 4.900.000
2007 24.330.000 79.86%
2008 33.910.000 28.25%
2009 21.438.000 -58.18%
2010 28.643.000 25.15%
2011 33.043.000 13.32%
2012 21.414.000 -54.31%
2013 12.805.000 -67.23%
2014 18.936.000 32.38%
2015 27.860.000 32.03%
2016 41.840.000 33.41%
2017 67.449.000 37.97%
2018 100.925.000 33.17%
2019 115.639.000 12.72%
2020 138.002.000 16.2%
2021 167.164.000 17.45%
2022 968.000.000 82.73%
2023 860.000.000 -12.56%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Zogenix, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 1.470.000
2007 4.730.000 68.92%
2008 11.820.000 59.98%
2009 14.102.000 16.18%
2010 51.270.000 72.49%
2011 60.459.000 15.2%
2012 49.494.000 -22.15%
2013 50.040.000 1.09%
2014 88.899.000 43.71%
2015 22.412.000 -296.66%
2016 20.994.000 -6.75%
2017 21.123.000 0.61%
2018 23.216.000 9.02%
2019 33.625.000 30.96%
2020 99.574.000 66.23%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Zogenix, Inc. EBITDA
Year EBITDA Growth
2006 -4.420.000
2007 -25.920.000 82.95%
2008 -42.748.000 39.37%
2009 -31.387.000 -36.2%
2010 -62.113.000 49.47%
2011 -74.684.000 16.83%
2012 -35.469.000 -110.56%
2013 -72.440.000 51.04%
2014 13.386.000 641.16%
2015 11.864.000 -12.83%
2016 -66.428.000 117.86%
2017 -123.748.000 46.32%
2018 -123.753.000 0%
2019 -418.233.000 70.41%
2020 -217.584.000 -92.22%
2021 -194.048.000 -12.13%
2022 2.242.000.000 108.66%
2023 1.520.000.000 -47.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Zogenix, Inc. Gross Profit
Year Gross Profit Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 9.753.000 100%
2011 17.078.000 42.89%
2012 23.477.000 27.26%
2013 10.529.000 -122.97%
2014 8.654.000 -21.67%
2015 4.481.000 -93.13%
2016 6.382.000 29.79%
2017 -908.000 802.86%
2018 0 0%
2019 3.648.000 100%
2020 13.101.000 72.15%
2021 99.864.000 86.88%
2022 3.101.000.000 96.78%
2023 2.608.000.000 -18.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Zogenix, Inc. Net Profit
Year Net Profit Growth
2006 -5.400.000
2007 -27.680.000 80.49%
2008 -45.570.000 39.26%
2009 -45.889.000 0.7%
2010 -73.564.000 37.62%
2011 -83.903.000 12.32%
2012 -47.386.000 -77.06%
2013 -80.856.000 41.39%
2014 8.587.000 1041.61%
2015 26.144.000 67.15%
2016 -69.707.000 137.51%
2017 -126.817.000 45.03%
2018 -123.914.000 -2.34%
2019 -419.503.000 70.46%
2020 -209.383.000 -100.35%
2021 -219.532.000 4.62%
2022 944.000.000 123.26%
2023 348.000.000 -171.26%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Zogenix, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 -108
2007 -395 72.66%
2008 -272 -45.22%
2009 -37 -655.56%
2010 -141 74.47%
2011 -16 -840%
2012 -5 -275%
2013 -6 20%
2014 0 0%
2015 1 100%
2016 -3 150%
2017 -5 50%
2018 -3 -33.33%
2019 -10 66.67%
2020 -4 -200%
2021 -4 0%
2022 4 200%
2023 1 -200%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Zogenix, Inc. Free Cashflow
Year Free Cashflow Growth
2007 -30.820.000
2008 -45.903.000 32.86%
2009 -34.420.000 -33.36%
2010 -75.394.000 54.35%
2011 -81.088.000 7.02%
2012 -52.495.000 -54.47%
2013 -45.730.000 -14.79%
2014 -80.938.000 43.5%
2015 -64.910.000 -24.69%
2016 -72.983.000 11.06%
2017 -75.950.000 3.91%
2018 -112.676.000 32.59%
2019 -121.011.000 6.89%
2020 -178.910.000 32.36%
2021 -41.126.000 -335.03%
2022 846.000.000 104.86%
2023 72.000.000 -1075%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Zogenix, Inc. Operating Cashflow
Year Operating Cashflow Growth
2007 -26.800.000
2008 -41.288.000 35.09%
2009 -32.361.000 -27.59%
2010 -71.952.000 55.02%
2011 -80.471.000 10.59%
2012 -52.202.000 -54.15%
2013 -44.920.000 -16.21%
2014 -80.816.000 44.42%
2015 -64.602.000 -25.1%
2016 -72.880.000 11.36%
2017 -75.874.000 3.95%
2018 -111.658.000 32.05%
2019 -111.519.000 -0.12%
2020 -167.531.000 33.43%
2021 -41.130.000 -307.32%
2022 1.569.000.000 102.62%
2023 176.000.000 -791.48%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Zogenix, Inc. Capital Expenditure
Year Capital Expenditure Growth
2007 4.020.000
2008 4.615.000 12.89%
2009 2.059.000 -124.14%
2010 3.442.000 40.18%
2011 617.000 -457.86%
2012 293.000 -110.58%
2013 810.000 63.83%
2014 122.000 -563.93%
2015 308.000 60.39%
2016 103.000 -199.03%
2017 76.000 -35.53%
2018 1.018.000 92.53%
2019 9.492.000 89.28%
2020 11.379.000 16.58%
2021 -4.000 284575%
2022 723.000.000 100%
2023 104.000.000 -595.19%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Zogenix, Inc. Equity
Year Equity Growth
2008 -77.534.000
2009 -122.300.000 36.6%
2010 28.734.000 525.63%
2011 9.312.000 -208.57%
2012 14.473.000 35.66%
2013 18.426.000 21.45%
2014 55.279.000 66.67%
2015 182.760.000 69.75%
2016 120.756.000 -51.35%
2017 301.521.000 59.95%
2018 522.801.000 42.33%
2019 245.059.000 -113.34%
2020 369.669.000 33.71%
2021 178.971.000 -106.55%
2022 7.508.000.000 97.62%
2023 6.007.000.000 -24.99%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Zogenix, Inc. Assets
Year Assets Growth
2008 27.625.000
2009 74.568.000 62.95%
2010 94.268.000 20.9%
2011 100.640.000 6.33%
2012 80.686.000 -24.73%
2013 112.504.000 28.28%
2014 202.835.000 44.53%
2015 305.987.000 33.71%
2016 231.505.000 -32.17%
2017 417.613.000 44.56%
2018 648.331.000 35.59%
2019 414.250.000 -56.51%
2020 651.130.000 36.38%
2021 468.489.000 -38.99%
2022 16.994.000.000 97.24%
2023 14.104.000.000 -20.49%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Zogenix, Inc. Liabilities
Year Liabilities Growth
2008 105.159.000
2009 196.868.000 46.58%
2010 65.534.000 -200.41%
2011 91.328.000 28.24%
2012 66.213.000 -37.93%
2013 94.078.000 29.62%
2014 147.556.000 36.24%
2015 123.227.000 -19.74%
2016 110.749.000 -11.27%
2017 116.092.000 4.6%
2018 125.530.000 7.52%
2019 169.191.000 25.81%
2020 281.461.000 39.89%
2021 289.518.000 2.78%
2022 9.486.000.000 96.95%
2023 8.097.000.000 -17.15%

Zogenix, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.52
Net Income per Share
-4.24
Price to Earning Ratio
-6.3x
Price To Sales Ratio
0x
POCF Ratio
-7.73
PFCF Ratio
0
Price to Book Ratio
8
EV to Sales
0.82
EV Over EBITDA
-0.33
EV to Operating CashFlow
-0.36
EV to FreeCashFlow
-0.36
Earnings Yield
-0.16
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,07 Bil.
Graham Number
17.82
Graham NetNet
0.42

Income Statement Metrics

Net Income per Share
-4.24
Income Quality
0.81
ROE
-0.83
Return On Assets
0.05
Return On Capital Employed
0.13
Net Income per EBT
0.68
EBT Per Ebit
0.8
Ebit per Revenue
0.09
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
1.75
Stock Based Compensation to Revenue
0.43
Gross Profit Margin
0.19
Operating Profit Margin
0.09
Pretax Profit Margin
0.07
Net Profit Margin
0.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.45
Free CashFlow per Share
-3.45
Capex to Operating CashFlow
0
Capex to Revenue
-0
Capex to Depreciation
-0.01
Return on Invested Capital
-0.59
Return on Tangible Assets
-0.61
Days Sales Outstanding
45.3
Days Payables Outstanding
1661
Days of Inventory on Hand
414.68
Receivables Turnover
8.06
Payables Turnover
0.22
Inventory Turnover
0.88
Capex per Share
-0

Balance Sheet

Cash per Share
5,62
Book Value per Share
3,33
Tangible Book Value per Share
1.53
Shareholders Equity per Share
3.33
Interest Debt per Share
3.42
Debt to Equity
0.94
Debt to Assets
0.36
Net Debt to EBITDA
-0.33
Current Ratio
3.63
Tangible Asset Value
0,08 Bil.
Net Current Asset Value
0,07 Bil.
Invested Capital
0.94
Working Capital
0,26 Bil.
Intangibles to Total Assets
0.21
Average Receivables
0,01 Bil.
Average Payables
0,02 Bil.
Average Inventory
3259000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Zogenix, Inc. Dividends
Year Dividends Growth
2022 0

Zogenix, Inc. Profile

About Zogenix, Inc.

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

CEO
Dr. Stephen Farr
Employee
218
Address
5959 Horton St Ste 500
Emeryville, 94608

Zogenix, Inc. Executives & BODs

Zogenix, Inc. Executives & BODs
# Name Age

Zogenix, Inc. Competitors